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To S. Stefani         August 23, 2018 
Editor in Chief 
Journal of Global Antimicrobial Resistance  
 
 
Enclosed please find the revised manuscript now entitled “Emergence of CTX-M-1-producing 
Salmonella enterica serovar Napoli: a novel “enzyme-pathogen association” in the Italian 
ESBL endemic context”, which I am resubmitting for possible publication as a Letter to the 
Editor in Journal of Global Antimicrobial Resistance. 
 
In this manuscript, we describe the first isolation of CTX-M-1-producing Salmonella enterica 
serovar Napoli from a clinical sample. This finding is strictly related to the Italian ESBL 
endemic context, in which uncommon associations enzyme-pathogen can be discovered. This 
serovar, relatively uncommon in Europe, is among the most common serovars causing infection 
in Italy. Moreover, Salmonella Napoli, especially in children, is often associated to invasive 
infections. The acquisition of resistance determinants by a so-diffused pathogen is a major 
cause of concern, making difficult the treatment of related infections.  
 
The manuscript has been revised according to reviewer’s comments and suggestions. The final 
version has been seen and approved by all the authors. The material is original, unpublished, 
and has not been simultaneously submitted to another medical journal. 
 
 
 
 
Yours sincerely, 
 
Francesco Luzzaro 
 
Please, address the correspondence concerning this manuscript to: 
Francesco Luzzaro, M.D. 
Mailing address: Microbiology and Virology Unit, A. Manzoni Hospital 
Via dell’Eremo, 9/11 - 23900 - Lecco, Italy 
Phone: +39 0341 489630  
Fax: +39 0341 489601 
E-mail: f.luzzaro@asst-lecco.it       
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Manuscript ID:  JGAR-D-18-00449 
Journal: Journal of Global Antimicrobial Resistance 
 
"First description of CTX-M-1-producing Salmonella enterica serovar Napoli: a new 
association enzyme-pathogen in the Italian ESBL endemic context" 
 
Point-by-point response 
 
Reviewer #1 
 
The authors describe a case of salmonellosis with a CTX-M-1 producing strain of Salmonella 
Napoli in Italy. It is a pity that not more was done to determine the properties of the blaCTX-
M-1 carrying plasmid.  
 
R: Additional information about the plasmid carrying the blaCTX-M-1 gene has been added in the 
text (see also response to point #4). 
 
All comments are mentioned below. 
 
1. Line 35: Please add the number of cases in this period of time in parenthesis. 
R: The number of cases has been added as requested. 
 
2. Line 34-38: Please shift this paragraph to the discussion below (e.g. line 60). 
R: The paragraph has been moved to the discussion. 
 
3. Line 50: Which method was used to determine the serovar? 
R: The method used to determine the serovar has been specified as requested. 
 
4. Line 59: How was the presence of only one plasmid confirmed without conjugation and 
plasmid isolation or plasmid number/size determination by S1 restriction and PFGE? PBRT 
just confirmed the presence of a replicon indicating the presence of at least one plasmid. 
Please rephrase. 
R: The sentence has been rephrased adding new information as follows: “Conjugation 
experiments using E. coli J53 recipient (rifampicin-resistant) performed at 37°C, and selecting 
on MacConkey plates containing ampicillin and rifampicin (both 50 µg/ml), were successful 
(efficiency, 4 x 10
-3
) and confirmed the presence of an IncI1 plasmid along with blaCTX-M-1”. 
 
5. Line 69-71: An acquisition of the ESBL gene within the gut from other 
Enterobacteriaceae could be possible - where the stool samples tested for presence of other 
ESBL-producing Enterobacteriaceae? 
R: We agree with this consideration. The acquisition of the ESBL gene within the gut from 
other Enterobacteriaceae could be possible. However, only selected stool pathogens (i.e., 
Salmonella, Shigella, and Campylobacter species) were searched for (according to our 
diagnostic routine methods). 
 
6. Line 71-74: Please delete this sentence - it is redundant. 
R: The sentence has been deleted as requested. 
*Detailed Response to Reviewers
 7. Line 78: Please discuss: Are 3rd generation cephalosporins used as treatment option 
for salmonellosis in children? 
R: The possible role of third-generation cephalosporins for treating salmonellosis in 
children  has been briefly discussed as requested. 
 
8. Line 79-82: The role of IncI1 finding is not discussed - what is its relevance in the 
"Italian context"? 
R: The role of IncI1 and the relevance in the Italian context have been briefly discussed as 
requested. 
 
9. Table 1: Please always use the standard three-letter-code for antibiotic names. 
R: The standard three-letter-code has been used in Table 1 as requested. 
 
 
Minor Comments 
 
Title: Please modify: "Emergence of CTX-M-1-producing Salmonella enterica serovar Napoli: 
a novel "enzyme-pathogen association" in the Italian ESBL endemic context". 
R: The title has been modified as requested. 
 
Line 32: Please delete "first". 
R: The word “first” has been deleted as requested. 
 
Line 35: Please write "main cause". 
R: The sentence has been modified as requested. 
 
Line 45: Please delete "each month". 
R: The sentence has been modified as requested. 
 
Line 46: Please delete "having the same features”. 
R: The sentence has been modified as requested. 
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Sir, 24 
In a recent nationwide survey, Giani et al. reported on the spread of extended-spectrum beta-25 
lactamase (ESBL) enzymes among Enterobacteriaceae isolated from both inpatients and 26 
outpatients, thus highlighting the Italian endemic context for these resistance determinants [1]. The 27 
CTX-M-1 group was the most common among ESBL enzymes (>80% of ESBL-producing 28 
enterobacterial isolates, including Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis). 29 
In this endemic scenario, ESBLs could be sometimes found in uncommon associations with other 30 
species. Here we describe the isolation of CTX-M-1-producing Salmonella enterica serovar Napoli 31 
from a clinical sample.  32 
On June 2017, we recovered a Salmonella Napoli from the stool culture of a one-year-old Italian 33 
girl, presenting diarrhea, abdominal pain and vomiting. The infant showed leukocytosis (12,000/l), 34 
without fever or other signs of invasive infection, hence no treatment was started. The child lived 35 
with the parents in Lombardy (Northern Italy, close to Milan) and did not attend the nursery school. 36 
Therefore, we speculated that the infection was attributable to the domestic environment or to 37 
family’s habits, though no other cases of infection were observed at the family level. Follow-up 38 
stool cultures performed for three consecutive months, were also positive for Salmonella Napoli, 39 
thus showing a persistent colonization at the intestinal level without signs and symptoms of 40 
infection. 41 
Bacterial identification at the genus level was conducted by MALDI-TOF mass spectrometry (Vitek 42 
MS, bioMérieux, Marcy l’Etoile, France), while serovar was determined by the regional Reference 43 
Laboratory for enterobacterial pathogens using the White-Kauffmann-Le Minor scheme 44 
(https://www.pasteur.fr/sites/default/files/veng_0.pdf). Antimicrobial susceptibility testing, carried 45 
out by broth microdilution using a dedicated TREK panel (DKMGN; Thermo Fisher Diagnostics, 46 
Milan, Italy) and interpreted according to the 7.1 EUCAST clinical breakpoints (www.eucast.org), 47 
3 
 
revealed that the isolate was non-susceptible to extended-spectrum cephalosporins, but susceptible 48 
to carbapenems, fluoroquinolones, colistin, tigecycline, and trimethoprim/sulfamethoxazole (Table 49 
1). The presence of an ESBL determinant was phenotypically evaluated on the basis of synergistic 50 
activity between clavulanate and extended-spectrum cephalosporins using the double disk 51 
approximation method (www.eucast.org). Molecular analyses carried out by CT103XL microarray 52 
system (Check-Points, Wageningen, The Netherlands) and PCR/sequencing revealed the presence 53 
of blaCTX-M-1 gene and a single IncI1 plasmid (PBRT kit; Diatheva, Cartoceto, Italy). Conjugation 54 
experiments using E. coli J53 recipient (rifampicin-resistant) performed at 37°C, and selecting on 55 
MacConkey plates containing ampicillin and rifampicin (both 50 µg/ml), were successful 56 
(efficiency, 4 x 10
-3
) and confirmed the presence of an IncI1 plasmid along with blaCTX-M-1. 57 
Salmonella Napoli is an emerging public health concern. During 2000–2006, a 140% increase in 58 
Salmonella Napoli cases was reported in Europe, mostly in France, Italy and Switzerland (87% of 59 
total cases) [2]. This serovar is one of the most common causing Salmonella infections in Italy, 60 
being on the rise since 2000 [3]. In Lombardy, Salmonella Napoli was the main cause of invasive 61 
salmonellosis among nontyphoidal serotypes (40 out of 687) during 2010-2014 [4]. Outbreaks of 62 
Salmonella Napoli infection reemerged in Italy during 2011–2015, with the proportion of related 63 
cases increased from 4.3% in 2011 to 5.8% in 2015 [5]. Salmonella Napoli is an important concern, 64 
especially in children, being often associated to invasive infections [4]. In a recent Italian study, 65 
compared to other serovars, the risk of Salmonella Napoli infection was higher in the age group <1-66 
year-old, and lower in the other age groups [3]. Its diffusion is mostly associated to waterborne and 67 
foodborne sources, although environmental and zoonotic sources have been suggested [3,5]. In 68 
particular, vegetables irrigated with contaminated water are the main food vehicle for Salmonella 69 
Napoli [5]. Of note, ESBL enzymes belonging to CTX-M-1 group are widely spread in E. coli 70 
strains isolated from animals and in the environment, probably explaining this uncommon 71 
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association with Salmonella Napoli. In our case, blaCTX-M-1 was carried by the IncI1 plasmid, that is 72 
considered a global epidemic resistance plasmid, being worldwide detected in Enterobacteriaceae 73 
of different origin. In particular, the IncI1 plasmid is widely diffused in Italy in E. coli strains of 74 
animal and human origin, being responsible for the dissemination of beta-lactamase genes, 75 
especially blaCTX-M-1.  76 
To the best of our knowledge, this is the first isolation of an ESBL-producing Salmonella Napoli 77 
from a clinical sample. In particular, the Italian ESBL endemic context could make real the 78 
acquisition of CTX-M-1 resistance determinant by this pathogen, representing a very worrisome 79 
occurrence, especially in the case of invasive infection in children. Furthermore, as a major concern, 80 
some outbreaks caused by Salmonella Napoli have been formerly described [5]. As widely diffused 81 
in E. coli, the association of ESBLs with other resistance determinants (i.e., those for 82 
fluoroquinolones and trimethoprim/sulfamethoxazole) could represent a possible occurrence also in 83 
Salmonella Napoli, making difficult the treatment of related infections. Of note, use of third-84 
generation cephalosporins is recommended for children at high risk for invasive disease. In this 85 
context, the prompt detection at the laboratory level of ESBL-producing Salmonella isolates is 86 
essential. Moreover, molecular and epidemiological investigations together with whole genome 87 
sequencing approaches conducted on clinical and environmental isolates could provide meaningful 88 
data to understand the exchange of resistance traits and the real sources of diffusion of this 89 
potentially problematic pathogen. 90 
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Sir, 24 
In a recent nationwide survey, Giani et al. reported on the spread of extended-spectrum beta-25 
lactamase (ESBL) enzymes among Enterobacteriaceae isolated from both inpatients and 26 
outpatients, thus highlighting the Italian endemic context for these resistance determinants [1]. The 27 
CTX-M-1 group was the most common among ESBL enzymes (>80% of ESBL-producing 28 
enterobacterial isolates, including Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis). 29 
In this endemic scenario, ESBLs could be sometimes found in uncommon associations with other 30 
species. Here we describe the isolation of CTX-M-1-producing Salmonella enterica serovar Napoli 31 
from a clinical sample.  32 
On June 2017, we recovered a Salmonella Napoli from the stool culture of a one-year-old Italian 33 
girl, presenting diarrhea, abdominal pain and vomiting. The infant showed leukocytosis (12,000/l), 34 
without fever or other signs of invasive infection, hence no treatment was started. The child lived 35 
with the parents in Lombardy (Northern Italy, close to Milan) and did not attend the nursery school. 36 
Therefore, we speculated that the infection was attributable to the domestic environment or to 37 
family’s habits, though no other cases of infection were observed at the family level. Follow-up 38 
stool cultures performed for three consecutive months, were also positive for Salmonella Napoli, 39 
thus showing a persistent colonization at the intestinal level without signs and symptoms of 40 
infection. 41 
Bacterial identification at the genus level was conducted by MALDI-TOF mass spectrometry (Vitek 42 
MS, bioMérieux, Marcy l’Etoile, France), while serovar was determined by the regional Reference 43 
Laboratory for enterobacterial pathogens using the White-Kauffmann-Le Minor scheme 44 
(https://www.pasteur.fr/sites/default/files/veng_0.pdf). Antimicrobial susceptibility testing, carried 45 
out by broth microdilution using a dedicated TREK panel (DKMGN; Thermo Fisher Diagnostics, 46 
Milan, Italy) and interpreted according to the 7.1 EUCAST clinical breakpoints (www.eucast.org), 47 
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revealed that the isolate was non-susceptible to extended-spectrum cephalosporins, but susceptible 48 
to carbapenems, fluoroquinolones, colistin, tigecycline, and trimethoprim/sulfamethoxazole (Table 49 
1). The presence of an ESBL determinant was phenotypically evaluated on the basis of synergistic 50 
activity between clavulanate and extended-spectrum cephalosporins using the double disk 51 
approximation method (www.eucast.org). Molecular analyses carried out by CT103XL microarray 52 
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MacConkey plates containing ampicillin and rifampicin (both 50 µg/ml), were successful 56 
(efficiency, 4 x 10
-3
) and confirmed the presence of an IncI1 plasmid along with blaCTX-M-1. 57 
Salmonella Napoli is an emerging public health concern. During 2000–2006, a 140% increase in 58 
Salmonella Napoli cases was reported in Europe, mostly in France, Italy and Switzerland (87% of 59 
total cases) [2]. This serovar is one of the most common causing Salmonella infections in Italy, 60 
being on the rise since 2000 [3]. In Lombardy, Salmonella Napoli was the main cause of invasive 61 
salmonellosis among nontyphoidal serotypes (40 out of 687) during 2010-2014 [4]. Outbreaks of 62 
Salmonella Napoli infection reemerged in Italy during 2011–2015, with the proportion of related 63 
cases increased from 4.3% in 2011 to 5.8% in 2015 [5]. Salmonella Napoli is an important concern, 64 
especially in children, being often associated to invasive infections [4]. In a recent Italian study, 65 
compared to other serovars, the risk of Salmonella Napoli infection was higher in the age group <1-66 
year-old, and lower in the other age groups [3]. Its diffusion is mostly associated to waterborne and 67 
foodborne sources, although environmental and zoonotic sources have been suggested [3,5]. In 68 
particular, vegetables irrigated with contaminated water are the main food vehicle for Salmonella 69 
Napoli [5]. Of note, ESBL enzymes belonging to CTX-M-1 group are widely spread in E. coli 70 
strains isolated from animals and in the environment, probably explaining this uncommon 71 
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association with Salmonella Napoli. In our case, blaCTX-M-1 was carried by the IncI1 plasmid, that is 72 
considered a global epidemic resistance plasmid, being worldwide detected in Enterobacteriaceae 73 
of different origin. In particular, the IncI1 plasmid is widely diffused in Italy in E. coli strains of 74 
animal and human origin, being responsible for the dissemination of beta-lactamase genes, 75 
especially blaCTX-M-1.  76 
To the best of our knowledge, this is the first isolation of an ESBL-producing Salmonella Napoli 77 
from a clinical sample. In particular, the Italian ESBL endemic context could make real the 78 
acquisition of CTX-M-1 resistance determinant by this pathogen, representing a very worrisome 79 
occurrence, especially in the case of invasive infection in children. Furthermore, as a major concern, 80 
some outbreaks caused by Salmonella Napoli have been formerly described [5]. As widely diffused 81 
in E. coli, the association of ESBLs with other resistance determinants (i.e., those for 82 
fluoroquinolones and trimethoprim/sulfamethoxazole) could represent a possible occurrence also in 83 
Salmonella Napoli, making difficult the treatment of related infections. Of note, use of third-84 
generation cephalosporins is recommended for children at high risk for invasive disease. In this 85 
context, the prompt detection at the laboratory level of ESBL-producing Salmonella isolates is 86 
essential. Moreover, molecular and epidemiological investigations together with whole genome 87 
sequencing approaches conducted on clinical and environmental isolates could provide meaningful 88 
data to understand the exchange of resistance traits and the real sources of diffusion of this 89 
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Table I. Characteristics and susceptibility profile of the CTX-M-1-producing Salmonella enterica serovar Napoli 
 
*MIC values indicate minimal inhibitory concentrations, as obtained by standard broth microdilution method. Interpretation based on EUCAST criteria 
(version 7.1, 2017; http://www.eucast.org). 
Abbreviations: AMC, amoxicillin-clavulanate; TZP, piperacillin-tazobactam; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; 
ETP, ertapenem; IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; TGC, tigecycline; CST, colistin; SXT, 
trimethoprim-sulfamethoxazole; CZA, ceftazidime-avibactam; CTT, ceftolozane-tazobactam;  S, susceptible; I, intermediate; R, resistant. 
 
Code Source 
Resistance 
determinant 
 MIC values (mg/L) of antimicrobial agents and clinical interpretation (S/I/R)*  
AMC TZP ATM CAZ CTX FEP ETP IPM MEM AMK GEN CIP TGC CST SXT CZA CTT 
LC0541/17 Stools 
 
CTX-M-1 
8/2 
(S) 
4/4 
(S) 
32 
(R) 
4 
(I) 
>8 
(R) 
4 
(I) 
≤0.12 
(S) 
≤0.5 
(S) 
≤0.12 
(S) 
≤4 
(S) 
≤0.5 
(S) 
≤0.06 
(S) 
≤0.25 
(S) 
0.5 
(S) 
≤1/19 
(S) 
≤0.5/4 
(S) 
1/4 
(S) 
Table
